hVIVO, a specialty biopharma company with discovery and clinical testing capabilities, announced the appointment of Dr Trevor Phillips as a Non-Executive Director, with immediate effect.
Phillips has more than thirty years’ experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities.
Phillips was previously COO and President of US Operations, as well as a member of the Board at Vectura Group, a company focused on respiratory diseases.
After joining Vectura in 2010, Phillips played an integral leadership role in the company’s successful development, including the acquisition of Activaero in 2014 and the merger with Skyepharma in 2016.
Prior to joining Vectura, Phillips held the roles of CEO and COO at Critical Therapeutics (now Chiesi USA), a US listed specialty pharmaceutical company.
Phillips also held senior management positions at Sepracor (now Sunovion Pharmaceuticals), Accenture and GlaxoWellcome (now GlaxoSmithKline).
Phillips trained as a microbiologist at the University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986.
Jaime Ellertson, Non-Executive Chairman, said: “I would like to welcome Dr Trevor Phillips to hVIVO. Trevor brings extensive respiratory drug development and commercialisation experience to hVIVO, which will play a vital role in guiding our partnering and collaboration strategies in respiratory and infectious diseases. We believe Trevor will strengthen the Board as we progress our precision medicine based inventions and products forward towards commercialisation.”
